An Assessment of the Use of Enoxaparin/Warfarin vs. Enoxaparin/Rivaroxaban in Patients with Gynecologic Cancer Co and Venous Thromboembolism

Authors

  • Marcos Renni Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil. Author
  • Ingrid Trugilho Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil. Author
  • Anke Bergmann Author

DOI:

https://doi.org/10.47363/JCRR/2021(3)128

Keywords:

Use of Enoxaparin, Warfarin vs. Enoxaparin, Rivaroxaban, Gynecologic Cancer , Venous Thromboembolism

Abstract

Venous thromboembolism (VTE), which consists of deep venous thrombosis and pulmonary embolism, is a frequent complication of cancer and its treatments. The presence of neoplasia increases about four to eight times the risk of thromboembolic events when compared to the general population. Cancer patients have several risk factors and pathogenic mechanisms that increase the likelihood of developing VTE. Changes in coagulation mechanisms are related to the progression of the disease, influencing the prognosis and survival [1-4].

Author Biographies

  • Marcos Renni, Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil.

    Marcos Renni, Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil.

     

  • Ingrid Trugilho, Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil.

    Ingrid Trugilho, Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil.

  • Anke Bergmann

    Anke Bergmann, Instituto Nacional do Câncer – INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brazil.

Downloads

Published

2025-11-22

Issue

Vol. 3 No. 1 (2021): Volume 3 Issue 1

Section

Articles